| Trial ID: | L2028 |
| Source ID: | NCT05443191
|
| Associated Drug: |
Semaglutide
|
| Title: |
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice
|
| Acronym: |
PIONEER REAL
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Semaglutide
|
| Outcome Measures: |
Primary: Change in Glycated haemoglobin (HbA1c ), Measured in percentage (%)-points, From baseline (week 0) to End of Study visit (V3) (week 34-44) | Secondary: Relative change in body weight, Measured in percentage (%), From baseline (week 0) to End of Study visit (V3) (week 34-44)|Absolute change in body weight, Measured in Kilogram (Kg), From baseline (week 0) to End of Study visit (V3) (week 34-44)|HbA1c < 7%, Measured as Yes or No, End of Study visit (V3) (week 34-44)|HbA1c reduction >=1%-points and body weight reduction of >=5%, Measured as Yes or No, From baseline (week 0) to End of Study visit (V3) (week 34-44)|HbA1c reduction >=1%-points and body weight reduction of >=3%, Measured as Yes or No, From baseline (week 0) to End of Study visit (V3) (week 34-44)|DTSQc, relative treatment satisfaction, Measured in Total score, End of Study visit (V3) (week 34- 44)|DTSQs, change in absolute treatment satisfaction, Measured in Total score, From baseline (week 0) to End of Study visit (V3) (week 34-44)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
50
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-10-20
|
| Completion Date: |
2023-04-27
|
| Results First Posted: |
|
| Last Update Posted: |
2024-09-19
|
| Locations: |
Master Centre for Finland, Helsinki, Finland, 00100, Finland|Aava Lääkärikeskus - Aava Kamppi, Annankatu 32, 00100 Helsinki, Finland, Helsinki,, 00100, Finland|Master centre for France_Paris La défense cedex, Paris, La Défense, cedex, France
|
| URL: |
https://clinicaltrials.gov/show/NCT05443191
|
